Olshan Client Biotechnology Value Fund’s Investments Highlighted

Firm News

BioWorld® 20th Anniversary Edition recently featured Olshan's client, Biotechnology Value Fund, in an article about the Fund’s investments in various pharmaceutical related companies including the Fund’s recent involvement with Avigen, Inc. and proposing a new model in which biotech shareholders are provided protection in this inherently risky business. Olshan represented Biotechnology Value Fund in its dealings with Avigen.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.